I hope we're in for a very good opening this morning! |
hTTps://www.londonstockexchange.com/news-article/GSK/statement-zantac-ranitidine-litigation/16621656 |
Yup, that's what I'll probably do |
Averaging up? |
Was hoping for a larger drop to add one final tranche but never mind. My average in price is 1510p over the last couple of weeks |
Great open bearing in mind ex div |
Minus 15 pence on the open, but GSK should recover most of it by the closing bell.. :o) |
Not always does a share price drop ('big' or otherwise) on x-div day. Even if it does, it more often regains the amount the same day or soon after. |
So big drop tomorrow then . |
x-div tomorrow .... ;0) |
1500-1600 took a month to cover, a way to go to get back to the April highs of 1800 before the Zantac press coverage and court case results came to light..
Good progress.. :o) |
 JO Hambro actively managing GSKLegal headwinds have battered GSK (GSK) and JOHCM manager Mark Costar is managing his position 'proactively' as the case takes new twists and turns.The Citywire Elite Companies AAA-rated pharmaceutical giant is the second-largest holding in Costar's JOHCM UK Dynamic fund, where it makes up 4.8% of the £502m portfolio.GSK has been battling legal litigation over its heartburn drug Zantac's links to cancer but Costar said he took the view that the legal battle and associated liabilities 'were already more than discounted in the price, masking an improving R&D productivity story and a broadening pipeline of attractive therapeutic assets'.However, the latest legal update saw a Delaware court reverse its decision on the key Daubert case which 'renewed uncertainty' and Costar said his original view 'at least in the short term... has proven to be misplaced'.'Despite strong first quarter results lending clear credence to the core fundamental story, and whilst an appeal has already begun and previous precedents lean heavily in favour of the equity at this juncture, we are not naïve enough to believe recovery can happen in the absence of this being resolved,' he said.'The shares are clearly very cheap, and the underlying progress is tangible, but we will manage the position size proactively in this period.'The shares gained 1.3% to £15.93 on Tuesday. |
GSK's upcoming ex-dividend date is Aug 15, 2024. Shareholders who own GSK stock before this date will receive the next dividend payment of 15p per share on Oct 10, 2024 |
That's not new news though |
Not to scare you but there are about 79k on the Delaware docket :/ |
How many more jury trials are yet to come? |
How sad are we ! |
You don't do anything Abdulla except pit in negative comments and troll gak . Sad really |
I buy when you dive,so dive,dive,dive . |
05 Aug 2024 08:51AMGSK : BERNSTEIN RAISES TARGET PRICE TO 2,610P FROM 2,560PThis news story contains no content |
Movement in the rate of the £ ? |
Yesterday it goes up when the market is undergoing a wider sell off. Today, on a "blue day" and with a hint of good news it goes down! Absolutely unfathomable! |
Will the share price not be affected by the global market meltdown yday? So good xantac news offset by this ? |
It seems the fat lady hasn't sung yet |
Think the market doesn't see any "read across" but I suspect it would have if GSK had lost |
Register to chat with like-minded investors on our interactive forums.
Hot Features
Premium
